SAMANTREE-MEDICAL
16.7.2024 07:01:34 CEST | Business Wire | Press release
SamanTree Medical, a leading medical technology company specializing in innovative solutions to improve the outcomes of surgery, today announced the closing of $14M as part of a Series B financing round. The new capital will be used to further develop and commercialize the Histolog® Scanner, expand its reach in Europe and the United States, and enhance its digital suite.
Revolutionizing Surgery with the Histolog® Scanner
The Histolog Scanner, a CE-marked device, allows for high-resolution imaging of fresh tissue surfaces during surgery, enabling pathologists and surgeons to perform real-time intra-operative assessment of resected tissue much faster than the conventional techniques. This innovative technology is based on ultra-fast confocal microscopy.
Investment
The round was led by Relyens Innovation Santé, advised by Turenne Capital, and saw participation from new investors Mutuelles Impact, Wille Finance, Noshaq and WE Life Sciences (Wallonie Entreprendre), along with returning investors Panakès Partners, BOM and b2venture. In conjunction with this financing round, SamanTree Medical will establish its headquarters and an operational base in Wallonia (Belgium), while the R&D operations will remain in Lausanne, Switzerland. Fraser Partners acted as sole financial advisor to SamanTree Medical SA.
Board of Directors Update
Joining the Board of Directors are Claire Poulard, Investment Director at Turenne Capital, and Henry Charlton, SVP and Chief Commercial & Marketing Officer at Intuitive. The new Board composition is as follows:
- Fabrizio Landi
- Claire Poulard
- Henry Charlton
- Dr. Charles Carignan (Chairman)
- Olivier Delporte (CEO)
CEO Olivier Delporte explained: “We are elated by the robust support from our investors, which highlights SamanTree Medical's impressive progress. This funding, coupled with our strengthened Board, will enable us to accelerate our innovation, expand globally, and enhance our digital solutions, thereby delivering greater value to patients. I also want to thank the Walloon investors WE Life Sciences and Noshaq for their continuing support and effort to strengthen the local life sciences ecosystem.”
“SamanTree Medical has demonstrated that the Histolog® Scanner can provide real-time, high-resolution imaging during surgery, and it has the potential to improve surgical outcomes. We are impressed with the company's performance and the clinical data supporting the use of the Histolog® Scanner in multiple soft-tissue surgical procedures. We look forward to partnering with SamanTree Medical to bring this transformative technology to more patients worldwide,” said Claire Poulard, Investment Director at Turenne Capital.
“I am excited to join the Board of SamanTree Medical at such a pivotal time for the company. The Histolog Scanner is a potentially significant advancement that provides surgeons with real-time actionable information to their decision-making,” said Henry Charlton, SVP and Chief Commercial Officer at Intuitive.
Strategic Vision and Global Expansion
As part of the financing conditions, SamanTree Medical is set to expand its commercial operations in Europe and is planning for US market entry later in 2024. This strategic move will involve scaling the deployment of the Histolog Scanner, bolstering clinical trials, and working to obtain necessary marketing authorizations from the U.S. FDA.
About SamanTree Medical and the Histolog Scanner
SamanTree Medical is dedicated to improving outcomes for patients undergoing surgery through innovative medical imaging solutions. The company has developed the Histolog Scanner, a novel device that offers real-time, high-resolution fresh tissue surface imaging during surgical procedures, that may significantly enhance the accuracy of tissue removal or biopsy. The Histolog Scanner covers a broad range of surgical applications in surgery and is currently commercialized in Europe. It is an investigational device in the US.
For more information, visit www.samantree.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715376136/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply: a New Study Shows that Agentic AI will Become a Strategic Alternative to Traditional Sourcing Models for 93% of Tech Leaders10.3.2026 11:26:00 CET | Press release
Reply [EXM, STAR: REY] today announced the release of “From Code to Control: AI’s Takeover of Software Development Lifecycle”, a commissioned study conducted by Forrester Consulting. The research, which surveyed 536 IT Executives across Europe and the US, highlights the progressive transition from simple AI coding assistants to autonomous agents capable of orchestrating the entire software development lifecycle (SDLC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310922600/en/ Silicon Shoring is Reply’s delivery model designed to leverage this shift toward Agentic AI. By using the Silicon Reply multi-agent system, this methodology offers a robust alternative to traditional offshoring. The study underscores a critical turning point for software development: as traditional offshoring models struggle with hidden costs and regulatory hurdles, 93% of organisations plan to adopt Agentic AI within the next two to three years a
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel10.3.2026 11:00:00 CET | Press release
WHOOP deepens investment in women’s physiology with clinically meaningful lab testing, predictive symptom modeling, and new Menstrual Cycle White Paper WHOOP, the human performance company, today unveiled multiple initiatives and new clinically-backed features, including the coming launch of the company’s Women's Health Specialized Blood Biomarker Panel. Building on the WHOOP Advanced Labs Baseline Panel launched last year, the Women’s Health Specialized Blood Biomarker Panel adds 11 clinically backed, female-specific blood biomarkers that expand insight into areas that are frequently under-measured or misinterpreted in traditional women’s health testing. WHOOP has also announced a new Hormonal Symptom Insights and Predictions update, along with a comprehensive Menstrual Cycle White Paper detailing the science behind its cycle modeling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310966566/en/ WHOOP Broadens WHOOP Adva
Spring into Smarter Home Protection: EZVIZ Launches Standout Deals for the Amazon Spring Sale10.3.2026 10:30:00 CET | Press release
As the new season brings longer days and fresh beginnings, EZVIZ is turning up the excitement with a lineup of irresistible offers during the Amazon Spring Sale. Known for delivering easy-to-use smart security products, EZVIZ is giving households the perfect opportunity to refresh their home protection with technology designed for modern living. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310567932/en/ Spring into smarter home protection: EZVIZ launches standout deals for the Amazon Spring Sale As homes open up to the energy of spring, whether welcoming guests, receiving more deliveries, or simply spending more time outdoors, this seasonal sales on Amazon offers a timely chance to upgrade everyday security. During the Spring Sale, shoppers can enjoy limited-time savings on a curated selection of EZVIZ’s smart cameras and entryway products, making it easier to safeguard front doors, gardens, and outdoor spaces while emb
For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 202510.3.2026 10:00:00 CET | Press release
Ferring's total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur®Continued ramp-up in the US for Adstiladrin®, our novel gene-based therapy for bladder cancer, confirming its position as Ferring’s second major growth driverCommitment to sustainability demonstrated by SBTi approval of our targets to reduce greenhouse gas emissions, and by our programme to reduce maternal deaths in low- and lower middle-income countries Ferring today published its 2025 Annual Report and Sustainability Report. The company achieved total revenues of over €2.5 billion in 2025, an increase of 7% over the previous year at actual exchange rates (AER) and 10% at constant exchange rates (CER). These were mainly driven by our flagship product Menopur® (menotropins for injection) in reproductive medicine, and the ramp-up in the US of our breakthrough gene-based therapy for non-muscle invasive bladder cancer, Adstiladrin® (nadofaragene firadenovec-
Quectel Unveils Versatile Pi Series SBCs to Power Developer Innovation10.3.2026 09:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of its range of Quectel Pi series of single-board computers (SBCs), designed for a broad range of industrial use cases. The portfolio currently includes three compact development platforms - the Quectel Pi M1, L1, and H1 boards - engineered for low power consumption, cost efficiency, and full-stack software support. Designed to accelerate prototyping and product development, they are well suited for embedded applications, IoT solutions, robotics projects, and edge computing deployments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310949640/en/ Quectel unveils versatile Pi series SBCs to power developer innovation “We’re delighted to launch the affordable, versatile, open source Quectel Pi series of SBCs to help developers of real IoT projects in areas such as home automation, robotics, sensors and edge computing to achiev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom